Find the right content for you
Have you received a letter out-of-the-blue recently from an unfamiliar agency asking you to pay a fee to register your European Patent application? Look out for the scam letters that look official, but aren't.
On 24 June 2020, the UK Supreme Court handed down its landmark judgment in Regeneron Pharmaceuticals Inc v Kymab Ltd [2020] UKSC 27 in a dispute that has been rumbling on for seven years. It was good news for Kymab and bad news for Regeneron, which saw two of its patents invalidated. For the rest of us, it’s an important case which includes key rulings on insufficiency.
A simple overview of the current status from IPOs. Last updated 18th May 2020.
The Covid-19 pandemic has prompted many companies to invest time and effort in developing technology that is aimed at helping care for, test, or treat people suffering from the disease. In normal times, these might be considered normal commercial activities and would be considered for patenting without a second thought. However, the fact that these developments are typically not being motivated by pure commercial gain, but by a desire to do something for the public good causes many companies to question whether or not they should seeks patents or any other form of intellectual property protection.
By clicking any link on this page you are giving your consent for us to set cookies.